Novo Nordisk reported that its GLP-1 obesity pill is starting faster than expected and lifted guidance, signaling improving demand momentum ahead of competitive pressure in the class. The company said adjusted sales and profits would shrink less than previously forecast, pointing to stronger prescription performance. The update comes as Novo tries to regain share after lagging in the obesity market versus Eli Lilly. Investors reacted positively to the “less-bad” outlook as the company continues to commercialize its new oral formulation in the U.S. The move highlights how early uptake curves for oral GLP-1 products are becoming a central driver of near-term earnings expectations, not just long-term trial outcomes. Novo also emphasized operational execution and pricing dynamics in its quarterly framing, consistent with a market where formulary access and payer behavior can swing prescription trends quickly.